BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10403525)

  • 1. Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.
    Vrana JA; Kramer LB; Saunders AM; Zhang XF; Dent P; Povirk LF; Grant S
    Biochem Pharmacol; 1999 Jul; 58(1):121-31. PubMed ID: 10403525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
    Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
    Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.
    Wang Z; Su ZZ; Fisher PB; Wang S; VanTuyle G; Grant S
    Exp Cell Res; 1998 Oct; 244(1):105-16. PubMed ID: 9770354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).
    Vrana JA; Saunders AM; Chellappan SP; Grant S
    Differentiation; 1998 May; 63(1):33-42. PubMed ID: 9615391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-beta-D-arabinofuranosylcytosine exposure.
    Vrana JA; Rao AS; Wang Z; Jarvis WD; Grant S
    Int J Oncol; 1998 Apr; 12(4):927-34. PubMed ID: 9499457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade.
    Vrana JA; Grant S
    Blood; 2001 Apr; 97(7):2105-14. PubMed ID: 11264178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
    Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
    Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
    Wang S; Vrana JA; Bartimole TM; Freemerman AJ; Jarvis WD; Kramer LB; Krystal G; Dent P; Grant S
    Mol Pharmacol; 1997 Dec; 52(6):1000-9. PubMed ID: 9396780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc.
    Chelliah J; Freemerman AJ; Wu-Pong S; Jarvis WD; Grant S
    Biochem Pharmacol; 1997 Sep; 54(5):563-73. PubMed ID: 9337072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine.
    Wang Z; Wang S; Fisher PB; Dent P; Grant S
    Differentiation; 2000 Aug; 66(1):1-13. PubMed ID: 10997587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apoptosis in human myeloid leukemia cells.
    Rao AS; Freemerman AJ; Jarvis WD; Chelliah J; Bear HD; Mikkelsen R; Grant S
    Leukemia; 1996 Jul; 10(7):1150-8. PubMed ID: 8683995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling.
    Jarvis WD; Fornari FA; Tombes RM; Erukulla RK; Bittman R; Schwartz GK; Dent P; Grant S
    Mol Pharmacol; 1998 Nov; 54(5):844-56. PubMed ID: 9804619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.
    Jarvis WD; Povirk LF; Turner AJ; Traylor RS; Gewirtz DA; Pettit GR; Grant S
    Biochem Pharmacol; 1994 Mar; 47(5):839-52. PubMed ID: 8135859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
    Wang S; Wang Z; Grant S
    Mol Pharmacol; 2003 Jan; 63(1):232-42. PubMed ID: 12488556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.
    Wang Z; Van Tuyle G; Conrad D; Fisher PB; Dent P; Grant S
    Cancer Res; 1999 Mar; 59(6):1259-67. PubMed ID: 10096557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.
    Cartee L; Maggio SC; Smith R; Sankala HM; Dent P; Grant S
    Mol Cancer Ther; 2003 Jan; 2(1):83-93. PubMed ID: 12533676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Boise L; Westin E; Howe C; Pettit GR; Turner A; McCrady C
    Biochem Pharmacol; 1991 Jul; 42(4):853-67. PubMed ID: 1867641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60).
    Freemerman AJ; Vrana JA; Tombes RM; Jiang H; Chellappan SP; Fisher PB; Grant S
    Leukemia; 1997 Apr; 11(4):504-13. PubMed ID: 9096690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
    Grant S; Jarvis WD; Swerdlow PS; Turner AJ; Traylor RS; Wallace HJ; Lin PS; Pettit GR; Gewirtz DA
    Cancer Res; 1992 Nov; 52(22):6270-8. PubMed ID: 1423273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.